Impact of the COVID-19 Pandemic on Central Precocious Puberty: a Retrospective Cohort Study from Turkey

NCT06823076 | Completed

• 1 other identifier: 406240
• Study Type: observational
• Target: 192
• Locations: 1 country
• Sites: 1

Brief Summary

Objective: This study investigates the clinical and demographic characteristics of girls diagnosed with central precocious puberty (CPP) in the pre-pandemic and pandemic periods to assess potential changes during the COVID-19 pandemic.

Conditions

COVID19- Infection with SARS-CoV-2 Virus

Keywords

Central precocious puberty, COVID-19 pandemic, GnRH analogs, pediatric endocrinology, lifestyle changes

Outcome Measures

Primary Outcomes (1)

• Mean Age at Pubertal Onset

  Mean Age at Pubertal Onset Description: The mean age at pubertal onset will be compared between pre-pandemic and post-pandemic periods in both girls and boys. Time Frame: At baseline. Method of Measurement: Tanner staging, LH/FSH levels, and bone age assessment.

  4 years

Study Arms (1)

prepandemic and pandemic precocious puberty groups were compared

Eligibility Criteria

• Age: Up to 18 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

The study included patients admitted to the Pediatric Endocrinology Departments of Umraniye Training and Research Hospital and Suleyman Demirel University, located in two different cities in Turkey. These patients were diagnosed with precocious puberty and treated with GnRH analogs before and after the COVID-19 pandemic. The patients were categorized into two groups: the pre-pandemic group (admitted and started GnRH analog treatment between March 2018 and March 2020) and the pandemic group (admitted and started GnRH analog treatment between March 2020 and March 2022), covering 24 months before and after the start of the pandemic lockdown

You may qualify if:

• Girls: Tanner stage ≥2 before age 8 peak LH \> on gnrh analog test, basal Lh \>0,3
• Patients with organic lesions (e.g., hypothalamo-pituitary tumors), congenital malformations, oncological diseases, neurosurgical or genetic disorders, or medications affecting puberty were excluded from the study

Sponsors & Collaborators

• Umraniye Education and Research Hospital: lead

Study Sites (1)

the Pediatric Endocrinology Departments of Umraniye Training and Research Hospital

Istanbul, Istanbul, 34764, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Puberty, Precocious; COVID-19

Condition Hierarchy (Ancestors)

Gonadal Disorders; Endocrine System Diseases; Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: CROSS SECTIONAL
• Target Duration: 4 Years
• Sponsor Type: OTHER GOV
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: MD

Study Record Dates

• First Submitted: February 11, 2025
• First Posted: February 12, 2025
• Study Start: March 1, 2018
• Primary Completion: March 1, 2022
• Study Completion: March 1, 2023
• Last Updated: February 12, 2025

Record last verified: 2023-02

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)